The short version of Gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-09 and is reviewed periodically as new material appears.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
=== 19 kDa Protein === This catalytic component of OpLuc has 196 amino acids with one cysteine in the carboxyl terminus and is distinct from proteins found in other luciferases. The protein is made up of two domains with repetitive sequencing of Ia-c and Ila-d in the peptide chain. It is thought to be the protein to cause the bioluminescent reaction of O.gracilirostris, but functions ineffectively without its larger, subunit counterpart. Although the crystal structure of OpLec has yet to be completely analyzed and mapped, 19 kDa experimentally expressed in mammalian cells (regarded as KAZ). The protein was isolated and mutated to catalyze a bright and sustained luminescent reaction to create an engineered luciferase, NanoLuc (NLuc), and a coelenterazine analogue (furimazine) to be used as a cellular reporter. Additional substrates with increased aqueous solubility (hydrofurimazine, fluorofurimazine, cephalofurimazine, and cephalofurimazine-9) were later developed.
=== Intestinal dialysis === In healthy humans, the intestines both remove uremic toxins (urea, creatine, uric acid) from blood and add uremic toxins (indoxyl sulfate, ammonia, etc.) to blood. More uremic toxins are excreted through the gut (as feces) than through the kidneys (as urine). This exchange of substances is enabled by the massive surface area of the intestinal capillary network and intestinal mucus, together serving as a large semipermeable membrane. In patients with kidney failure, the intestines receive a larger influx of uremic toxins due to a higher concentration in blood, but this does not automatically translate to a benefit in reducing blood toxin levels as gut bacteria use these toxins as food, producing more toxins in the process. The goal of intestinal dialysis is to maximize the removal of uremic toxins into the intestines while minimizing the production of new toxin molecules in the intestines. It serves as a more conservative renal replacement therapy for those unable to tolerate conventional dialysis. There are a few forms of intestinal dialysis:
from the Pliocene strata of Mininco Formation (Chile), extending known distribution of capybaras west of the Andes. Selvatici et al. (2026) determine a previously unidentified mummified animal from the Homestake Gulch site (Yukon, Canada) as a late Holocene (approximately 3000-years-old) New World porcupine, report the recovery of the first complete ancient mitochondrial genome of a member of this species, and interpret this finding as evidence of appearance of the New World porcupines in the studied area after the appearance of the boreal forest in the aftermath of the Last Glacial Period. Carrillo et al. (2026) study the evolutionary history of caviomorph rodents on the basis of data from extant and extinct members of the group, providing evidence of different trajectories of taxonomic and morphological diversification of Chinchilloidea and Octodontoidea. Evidence from the study of tooth wear of caviomorph rodents from the Paleogene strata of the Shapaja in Peruvian Amazonia, indicative of diverse dietary strategies of the studied rodents, is presented by Robinet et al. (2026). Gutstein et al. (2026) describe fossil material of a member of the genus Cardiatherium from the Bahía Inglesa Formation (Chile), providing evidence of wetter environmental conditions in the area of present-day Pacific coast of the Atacama Desert during the late Miocene. Delinschi et al. (2026) confirm the validity of Sarmatosminthus gabuniai on the basis of the analysis of fossil material from Vallesian sites in Moldova, Romania and Ukraine.
== Further reading == Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part I. Pathophysiology". Journal of the American Academy of Dermatology. 62 (3): 361–70, quiz 371–2. doi:10.1016/j.jaad.2009.10.042. PMID 20159304. Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part II. Advances and controversies". Journal of the American Academy of Dermatology. 62 (3): 373–84, quiz 385–6. doi:10.1016/j.jaad.2009.10.041. PMID 20159305.
=== Ethnicity === According to the 2021 census, 472,250 residents identified as members of visible minority groups in Scarborough census tracts, comprising 76.8 percent of the total population of the district. According to the prior census conducted in 2016, the visible minority population numbered 453,570, comprising 73.9 percent of the total population of the district. The district has one of the largest concentration of Sri Lankan Tamils outside Sri Lanka.
Sources: en.wikipedia.org
Even before the partitions from the late 18th century, the Russian Empire had already acquired some territories of the Polish–Lithuanian Commonwealth (a real union of Kingdom of Poland with the Grand Duchy of Lithuania). The first Russian partition took place in the late 17th century when the forced Treaty of Andrusovo signed in 1667 granted Russia the Commonwealth's territory in the Eastern Ukraine. Under the Third Partition of Poland Russia acquired Courland, all Lithuanian territory east of the Nieman River, and the remaining parts of Volhynian Ukraine.
===== Iron recycling and loss ===== Most of the iron in the body is hoarded and recycled by the reticuloendothelial system, which breaks down aged red blood cells. In contrast to iron uptake and recycling, there is no physiologic regulatory mechanism for excreting iron. People lose a small but steady amount by gastrointestinal blood loss, sweating and by shedding cells of the skin and the mucosal lining of the gastrointestinal tract. The total amount of loss for healthy people in the developed world amounts to an estimated average of 1 mg a day for men, and 1.5–2 mg a day for women with regular menstrual periods. People with gastrointestinal parasitic infections, more commonly found in developing countries, often lose more. Those who cannot regulate absorption well enough get disorders of iron overload. In these diseases, the toxicity of iron starts overwhelming the body's ability to bind and store it.
After the formation of the State Union of Serbia and Montenegro, the Yugoslav tricolour was to be replaced by a new compromise flag. Article 23 of the Law for the implementation of the Constitutional Charter stated that a law specifying the new flag was to be passed within 60 days of the first session of the new joint parliament. Among the flag proposals, the popular choice was a flag with a shade of blue in between the Serbian tricolor and the Montenegrin tricolor of 1993 through 2004. The color shade Pantone 300C was perceived as the best choice. However, the parliament failed to vote on the proposal within the legal time-frame. In 2004, Montenegro adopted a radically different flag, as its independence-leaning government sought to distance itself from Serbia. Proposals for a compromise flag were dropped after this and the Union of Serbia and Montenegro never adopted a flag. A similar fate befell the country's state anthem and coat-of-arms to be; the above-mentioned Article 23 also stipulated that a law determining the State Union's flag and anthem was to be passed by the end of 2003. The official proposal for a state anthem was a combination piece consisting of one verse of the former (now current) Serbian national anthem "Bože pravde" followed by a verse of the Montenegrin folk song, "Oj, svijetla majska zoro". This proposal was dropped after some public opposition, notably by Serbian Patriarch Pavle. Another legal deadline passed and no state anthem was adopted.
=== Food sources === Dietary selenium comes from nuts, cereals, meat, mushrooms, fish, and eggs. Brazil nuts are the richest ordinary dietary source and could cause selenium toxicity if consumed regularly – though the actual concentration of selenium (as with any plant-based food sources, such as another selenium-accumulating "paradise nut" Lecythis, belonging to the same family Lecythidaceae) is soil-dependent and may vary significantly by geographic location. In descending order of concentration, high levels are also found in kidney, tuna, crab, and lobster. The human body's content of selenium is believed to be in the 13–20 milligram range.
==== Cytotoxic antibiotics ==== The cytotoxic antibiotics are a varied group of drugs that have various mechanisms of action. The common theme that they share in their chemotherapy indication is that they interrupt cell division. The most important subgroup is the anthracyclines and the bleomycins; other prominent examples include mitomycin C and actinomycin. Among the anthracyclines, doxorubicin and daunorubicin were the first, and were obtained from the bacterium Streptomyces peucetius. Derivatives of these compounds include epirubicin and idarubicin. Other clinically used drugs in the anthracycline group are pirarubicin, aclarubicin, and mitoxantrone. The mechanisms of anthracyclines include DNA intercalation (molecules insert between the two strands of DNA), generation of highly reactive free radicals that damage intercellular molecules and topoisomerase inhibition. Actinomycin is a complex molecule that intercalates DNA and prevents RNA synthesis. Bleomycin, a glycopeptide isolated from Streptomyces verticillus, also intercalates DNA, but produces free radicals that damage DNA. This occurs when bleomycin binds to a metal ion, becomes chemically reduced and reacts with oxygen. Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.